SHANGHAI and HONG KONG, Aug. 24, 2026 /PRNewswire/ -- Antengene Corporation Limited (" Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, today announced that the Phase I ATTRACT study of our proprietary ATG-201, a CD19/CD3 bispecific T-cell engager antibody for B cell-related autoimmun

• Omlyclo® (omalizumab) 300 mg launched in key European markets including Germany, the UK and France, with rollout to expand across Europe by year-end • Omlyclo® 300 mg strength available in both pre-filled syringe (PFS) and autoinjector (AI) presentations • Multiple dose strengths and device options broaden treatment flexibility for healthcare professionals INCHEON, SOUTH KOREA – Celltrion (KRX: 068270) today announced the launch of the 300 mg strength of Omlyclo® (omalizumab), a treatment for

- ASP2138's advancement into Phase 3 marks an important milestone in Astellas' commitment to advancing research in CLDN18.2 with its differentiated portfolio, spanning approved treatments and investigational assets - TOKYO, Aug. 24, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the first patient has been dosed in a Phase 3 study evaluating ASP2138 in combination with chemotherapy and pembrolizumab as first-line treatment

IMAAVY is an immunoselective FcRn blocker designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies while also preserving B-cell function Warm autoimmune hemolytic anemia is a rare, life-threatening disease in which autoantibodies cause the destruction of red blood cells, leading to severe anemia and debilitating fatigue The approval is based on the pivotal Phase 2/3 study which demonstrated durable hemoglobin responsea A mean increase in hemoglobin of 1 g/dL at Week 1b and

MIAMI, Aug. 24, 2026 /PRNewswire/ -- BreakBio, the third player in personalized drugs after Moderna and BioNTech and the top private company in the personalized drugs space with advanced cutting-edge technology, is entering the clinic next quarter. BreakBio aims to be not first-in-class but best-in-class. It is designed for both higher efficacy than Moderna or BioNTech and it is also designed to treat more cancer indications than Moderna or BioNTech. Continue Reading BreakBio is designed for hig

This milestone brings complex cardiothoracic surgical care closer to home for patients in Hernando County and surrounding communities, backed by the expertise and resources of Tampa General's academic health system. TAMPA, Fla., Aug. 24, 2026 /PRNewswire/ -- Tampa General Hospital (TGH) Brooksville has reached a significant clinical milestone with the successful completion of its first cardiothoracic surgical procedure, expanding access to advanced heart care for patients in Hernando County and

Patented alternative preserved nicotine-like activity at key satisfaction-related receptors while producing a markedly more favorable in vitro cytotoxicity result than nicotine under the conditions tested. PHOENIX, Aug. 24, 2026 /PRNewswire/ -- Bonguard Naturals today announced results from a new nonclinical study that could open a new chapter in adult nicotine alternatives to advance tobacco harm reduction. Instead of simply changing the device, flavor or delivery format, Nixodine-S™ is designe

SAN ANTONIO, Aug. 24, 2026 /PRNewswire/ -- UT Health San Antonio, the academic health center and health system of The University of Texas at San Antonio (UT San Antonio), has named nationally recognized blood cancer and cellular therapy expert Georg Aue, MD, PhD, MBA, the director of the Stem Cell Transplant and Cellular Therapy Program at the Mays Cancer Center, the only National Cancer Institute (NCI)-designated Cancer Center in South Texas. He will also serve as the inaugural director of the

Company announcement No. 41 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 34, 2026) Copenhagen, Denmark, August 24, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 34 (August 17 - August 21, 2026). The Program is carried out in accordance with Article 5 of R

Seasoned Executive Brings Track Record of Drug Launches, External Innovation, and Portfolio Growth at Bristol Myers Squibb, Wyeth, Bayer, and Danaher to BRC's Next Phase of Growth MONTEREY, Calif., Aug. 24, 2026 /PRNewswire/ -- BRC Therapeutics (BRC), a clinical-stage pharmaceutical company developing multimodal cannabinoid therapeutics for neurological and inflammatory conditions, today announced the appointment of Chandra Ramanathan, Ph.D., M.B.A., as Executive Vice President of Commercializat